BioXcel Therapeutics's Alzheimer's Drug Trial Success Overshadowed by Fraud Investigation and Site Issues
BioXcel Therapeutics announced that its experimental drug, BXCL501, has met the main goal of reducing acute agitation in Alzheimer's patients in a late-stage study. However, concerns over data integrity at one of the trial sites have marred the results. The drug showed statistically significant reduction in agitation after two hours compared to a placebo, but did not meet another key target at 30 minutes. BioXcel plans to submit an application to expand the drug's use later this year, but will also conduct an investigation into the data integrity issue.